J. Lewis

发表

A More Accurate Method To Estimate Glomerular Filtration Rate from Serum Creatinine: A New Prediction Equation

A. Levey, J. Bosch, J. Lewis, 1999, Annals of Internal Medicine.

Comparison of drug dosing recommendations based on measured GFR and kidney function estimating equations.

C. Schmid, L. Stevens, A. Levey, 2009, American journal of kidney diseases : the official journal of the National Kidney Foundation.

Cardiac diseases in maintenance hemodialysis patients: results of the HEMO Study.

M. Rocco, A. Cheung, A. Levey, 2004, Kidney international.

A computerized provider order entry intervention for medication safety during acute kidney injury: a quality improvement report.

Allison B McCoy, Jonathan S Schildcrout, Lemuel R Waitman, 2010, American journal of kidney diseases : the official journal of the National Kidney Foundation.

Diabetic nephropathy in patients with Type II diabetes

J. Lewis, 2000 .

Government Quality Measures: First Do No Harm

J. Lewis, J. B. Lewis, 2015, Seminars in dialysis.

Serum Bicarbonate and Kidney Disease Progression and Cardiovascular Outcome in Patients With Diabetic Nephropathy: A Post Hoc Analysis of the RENAAL (Reduction of End Points in Non-Insulin-Dependent Diabetes With the Angiotensin II Antagonist Losartan) Study and IDNT (Irbesartan Diabetic Nephropathy

J. Lewis, B. Wolffenbuttel, D. de Zeeuw, 2015, American journal of kidney diseases : the official journal of the National Kidney Foundation.

Multinephron Segment Diuretic Therapy to Overcome Diuretic Resistance in Acute Heart Failure: A Single-Center Experience

J. Lewis, J. Arroyo, A. Guide, 2021 .

Self-Motivation Is Associated With Phosphorus Control in End-Stage Renal Disease.

K. Wallston, T. Ikizler, J. Lewis, 2015, Journal of renal nutrition : the official journal of the Council on Renal Nutrition of the National Kidney Foundation.

Health care providers’ support of patients’ autonomy, phosphate medication adherence, race and gender in end stage renal disease

K. Wallston, J. Lewis, T. Browne, 2016, Journal of Behavioral Medicine.

Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure.

Deepak L. Bhatt, P. Ponikowski, Lawrence A Leiter, 2020, The New England journal of medicine.

Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease.

Deepak L. Bhatt, Lawrence A Leiter, R. Diaz, 2020, The New England journal of medicine.

Diabetic Kidney Disease: The Tiger May Have New Stripes.

J. Lewis, K. Umanath, 2018, American journal of kidney diseases : the official journal of the National Kidney Foundation.

Nonproteinuric diabetic nephropathy: when diabetics don't read the textbook.

J. Lewis, J. Dwyer, 2013, The Medical clinics of North America.

When Diabetics Don't Read the Textbook

J. Lewis, J. Dwyer, 2013 .

Renal Dysfunction in the Presence of Normoalbuminuria in Type 2 Diabetes: Results from the DEMAND Study

H. Parving, G. Remuzzi, J. Lewis, 2011, Cardiorenal Medicine.

Adverse drug events during AKI and its recovery.

A. McCoy, E. Siew, J. Peterson, 2013, Clinical journal of the American Society of Nephrology : CJASN.

Managing Hypertension in Patients with CKD: A Marathon, Not a SPRINT.

A. Cheung, J. Lewis, R. Toto, 2016, Journal of the American Society of Nephrology : JASN.

ACE inhibitors versus angiotensin receptor blockers in diabetic nephropathy: is there a winner?

E. Lewis, J. Lewis, 2004, Journal of the American Society of Nephrology : JASN.

Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial.

Tom Greene, Lawrence J Appel, Lee Hebert, 2002, JAMA.

Impact of irbesartan, blood pressure control, and proteinuria on renal outcomes in the Irbesartan Diabetic Nephropathy Trial.

E. Lewis, R. Atkins, J. Lewis, 2004, Kidney international. Supplement.

Association of gadolinium based magnetic resonance imaging contrast agents and nephrogenic systemic fibrosis.

Sam S. Chang, J. Lewis, G. Bhave, 2008, The Journal of urology.

Evaluation of Renal Artery Stenosis in Dialysis Patients

J. Lewis, J. Dwyer, B. Greco, 2009, Seminars in dialysis.

Relative incidence of ESRD versus cardiovascular mortality in proteinuric type 2 diabetes and nephropathy: results from the DIAMETRIC (Diabetes Mellitus Treatment for Renal Insufficiency Consortium) database.

R. Atkins, J. Lewis, D. de Zeeuw, 2012, American journal of kidney diseases : the official journal of the National Kidney Foundation.

Olmesartan to prevent the development of microalbuminuria: is it new? Is it true? Is it important?

J. Lewis, J. Dwyer, 2011, American journal of kidney diseases : the official journal of the National Kidney Foundation.

Mixed‐effects models for slope‐based endpoints in clinical trials of chronic kidney disease

H. Tighiouart, J. Lewis, T. Greene, 2019, Statistics in medicine.

Treating diabetic nephropathy: unfinished success is not failure.

J. Lewis, 2007, Clinical journal of the American Society of Nephrology : CJASN.

The effects of weight change on glomerular filtration rate.

Jackson T. Wright, B. Astor, L. Appel, 2015, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

Impact of Baseline Renal Function on the Efficacy and Safety of Aliskiren Added to Losartan in Patients With Type 2 Diabetes and Nephropathy

E. Lewis, H. Parving, J. Lewis, 2010, Diabetes Care.

Rebuttal of the Pro View: Albuminuria Is an Appropriate Therapeutic Target in Patients with CKD.

J. Lewis, L. Fried, 2015, Clinical journal of the American Society of Nephrology : CJASN.

Pyridoxamine Dihydrochloride in Diabetic Nephropathy (PIONEER-CSG-17): Lessons Learned from a Pilot Study

J. Lewis, J. Dwyer, B. Greco, 2014, Nephron.

Pyridorin in type 2 diabetic nephropathy.

E. Lewis, T. Berl, R. Atkins, 2012, Journal of the American Society of Nephrology : JASN.

Effects of sulodexide in patients with type 2 diabetes and persistent albuminuria.

J. Lewis, T. Greene, H. Heerspink, 2008, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

A randomized trial of a 6-week course of celecoxib on proteinuria in diabetic kidney disease.

J. Lewis, R. Rodby, Y. Shyr, 2007, American journal of kidney diseases : the official journal of the National Kidney Foundation.

Microalbuminuria as a target to improve cardiovascular and renal outcomes in diabetic patients

J. Lewis, S. Basi, 2007, Current diabetes reports.

Increasing telmisartan vs amlodipine dose in patients with hypertension, type 2 diabetes and microalbuminuria

J. Lewis, 2007, Nature Clinical Practice Nephrology.

Microalbuminuria as a target to improve cardiovascular and renal outcomes.

J. Lewis, S. Basi, 2006, American journal of kidney diseases : the official journal of the National Kidney Foundation.

Clinically unrecognized Q-wave myocardial infarction in patients with diabetes mellitus, systemic hypertension, and nephropathy.

M. Pfeffer, J. Rouleau, E. Lewis, 2004, The American journal of cardiology.

Comparative performance of the CKD Epidemiology Collaboration (CKD-EPI) and the Modification of Diet in Renal Disease (MDRD) Study equations for estimating GFR levels above 60 mL/min/1.73 m2.

Christopher H Schmid, Michael Mauer, Tom Greene, 2010, American journal of kidney diseases : the official journal of the National Kidney Foundation.

Sulodexide for kidney protection in type 2 diabetes patients with microalbuminuria: a randomized controlled trial.

E. Lewis, T. Berl, R. Atkins, 2011, American journal of kidney diseases : the official journal of the National Kidney Foundation.

Validation of creatinine-based estimates of GFR when evaluating risk factors in longitudinal studies of kidney disease.

Lawrence Appel, Tom Greene, Janice Lea, 2006, Journal of the American Society of Nephrology : JASN.

Impact of glycaemic control on the effect of direct renin inhibition in the AVOID study

E. Lewis, H. Parving, J. Lewis, 2012, Journal of the renin-angiotensin-aldosterone system : JRAAS.

Impact of aliskiren treatment on urinary aldosterone levels in patients with type 2 diabetes and nephropathy: an AVOID substudy

E. Lewis, J. Lewis, N. Hollenberg, 2012, Journal of the renin-angiotensin-aldosterone system : JRAAS.

Comparison of causes of death using HEMO Study and HCFA end-stage renal disease death notification classification systems. The National Institutes of Health-funded Hemodialysis. Health Care Financing Administration.

M. Rocco, A. Levey, J. Lewis, 2002, American journal of kidney diseases : the official journal of the National Kidney Foundation.

Original Investigation The Phosphate Binder Ferric Citrate and Mineral Metabolism and Inflammatory Markers in Maintenance Dialysis Patients: Results From Prespecified Analyses of a Randomized Clinical Trial

J. Lewis, T. Greene, M. Koury, 2015 .

The Phosphate Binder Ferric Citrate and Mineral Metabolism and Inflammatory Markers in Maintenance Dialysis Patients: Results From Prespecified Analyses of a Randomized Clinical Trial.

J. Lewis, T. Greene, M. Koury, 2015, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[Aliskiren combined with losartan in type 2-diabetes and nephropathy - secondary publication].

E. Lewis, H. Parving, J. Lewis, 2009, Ugeskrift for laeger.

Multi-Nephron Segment Diuretic Therapy to Overcome Diuretic Resistance in Acute Heart Failure: A Single-Center Experience.

J. Lewis, J. Arroyo, A. Guide, 2021, Journal of cardiac failure.

"Dip" in eGFR: Stay the Course With SGLT-2 Inhibition.

J. Lewis, J. Testani, K. Umanath, 2022, Circulation.

Diabetic Proteinuria Revisited: Updated Physiologic Perspectives

J. Lewis, I. Raz, S. Heyman, 2022, Cells.

Dose-response and efficacy of ferric citrate to treat hyperphosphatemia in hemodialysis patients: a short-term randomized trial.

J. Lewis, M. Koury, M. Kaplan, 2013, American journal of kidney diseases : the official journal of the National Kidney Foundation.

Aliskiren combined with losartan in type 2 diabetes and nephropathy.

E. Lewis, H. Parving, J. Lewis, 2008, The New England journal of medicine.

Update on Diabetic Nephropathy: Core Curriculum 2018.

J. Lewis, K. Umanath, 2018, American journal of kidney diseases : the official journal of the National Kidney Foundation.

Phosphorus binding with ferric citrate is associated with fewer hospitalizations and reduced hospitalization costs

J. Lewis, R. Rodby, J. Dwyer, 2015, Expert review of pharmacoeconomics & outcomes research.

Intensive blood-pressure control in hypertensive chronic kidney disease.

Keith C. Norris, Jackson T. Wright, B. Astor, 2010, The New England journal of medicine.

CHAPTER 64 – Thromboembolic Renovascular Disease

J. Lewis, J. Dwyer, B. Greco, 2010 .

Proteinuria reduction and progression to renal failure in patients with type 2 diabetes mellitus and overt nephropathy.

E. Lewis, E. Briganti, R. Atkins, 2005, American journal of kidney diseases : the official journal of the National Kidney Foundation.

The Safety and Tolerability of Ferric Citrate as a Phosphate Binder in Dialysis Patients

J. Lewis, T. Greene, M. Koury, 2012, Nephron Clinical Practice.

Managing hyperphosphatemia in patients with chronic kidney disease on dialysis with ferric citrate: latest evidence and clinical usefulness

J. Lewis, U. Bhatt, S. Fadem, 2015, Therapeutic advances in chronic disease.

Rationale and study design of a three‐period, 58‐week trial of ferric citrate as a phosphate binder in patients with ESRD on dialysis

J. Lewis, M. Koury, G. Schulman, 2013, Hemodialysis international. International Symposium on Home Hemodialysis.

Membranous nephropathy with crescents.

J. Lewis, A. Fogo, J. Dwyer, 2011, Journal of the American Society of Nephrology : JASN.

Impact of achieved blood pressure on cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial.

J. Rouleau, E. Lewis, T. Berl, 2005, Journal of the American Society of Nephrology : JASN.

Focus on health information technology, electronic health records and their financial impact: A framework for evaluating the appropriateness of clinical decision support alerts and responses

Randolph A. Miller, Lemuel R. Waitman, Allison B. McCoy, 2012, J. Am. Medical Informatics Assoc..

Real-time pharmacy surveillance and clinical decision support to reduce adverse drug events in acute kidney injury

Allison B McCoy, Lemuel R Waitman, Josh F Peterson, 2012, Applied Clinical Informatics.

Concurrent and discrete clinicopathological presentations of Wegener granulomatosis and anti-glomerular basement membrane disease.

J. Lewis, A. Fogo, S. Clyne, 2009, American journal of kidney diseases : the official journal of the National Kidney Foundation.

Moderation of dietary sodium potentiates the renal and cardiovascular protective effects of angiotensin receptor blockers.

H. Parving, J. Lewis, G. Navis, 2012, Kidney international.

Sulodexide fails to demonstrate renoprotection in overt type 2 diabetic nephropathy.

E. Lewis, T. Berl, J. Chan, 2012, Journal of the American Society of Nephrology : JASN.

Cardiovascular outcomes in the African American Study of Kidney Disease and Hypertension (AASK) Trial.

Keith C. Norris, L. Appel, J. Lewis, 2006, American journal of kidney diseases : the official journal of the National Kidney Foundation.

Body mass index and chronic kidney disease outcomes after acute kidney injury: a prospective matched cohort study

J. Kaufman, A. Garg, A. Go, 2021, BMC Nephrology.

Opioid Use in Hemodialysis Patients.

J. Lewis, Sharmeela Saha, R. Olivo, 2015, American journal of kidney diseases : the official journal of the National Kidney Foundation.

Anti-TGF-β1 Antibody Therapy in Patients with Diabetic Nephropathy.

J. Lewis, T. Greene, K. Duffin, 2017, Journal of the American Society of Nephrology : JASN.

Microalbuminuria in Type 2 Diabetes and Hypertension

J. Lewis, P. Fesler, A. Mimran, 2008, Diabetes Care.

Bilirubin and Progression of Nephropathy in Type 2 Diabetes: A Post Hoc Analysis of RENAAL With Independent Replication in IDNT

J. Lewis, G. Navis, D. de Zeeuw, 2014, Diabetes.

Accuracy of a GFR estimating equation over time in people with a wide range of kidney function.

G. Beck, C. Schmid, H. Tighiouart, 2012, American journal of kidney diseases : the official journal of the National Kidney Foundation.

Diabetic Nephropathy for the Primary Care Physician : More than Microalbuminuria

J. Lewis, P. Chuang, J. Giullian, 2007 .

GFR Estimation Using β-Trace Protein and β2-Microglobulin in CKD.

G. Beck, J. Coresh, H. Tighiouart, 2016, American journal of kidney diseases : the official journal of the National Kidney Foundation.

Relationship between body mass index and proteinuria in hypertensive nephrosclerosis: results from the African American Study of Kidney Disease and Hypertension (AASK) cohort.

J. Lewis, T. Greene, R. Toto, 2010, American journal of kidney diseases : the official journal of the National Kidney Foundation.

Ferric Citrate, an Iron-Based Phosphate Binder, Reduces Health Care Costs in Patients on Dialysis Based on Randomized Clinical Trial Data

J. Lewis, R. Rodby, J. Dwyer, 2015, Drugs in R&D.

Ferric Citrate Reduces Intravenous Iron and Erythropoiesis-Stimulating Agent Use in ESRD.

J. Lewis, T. Greene, M. Koury, 2015, Journal of the American Society of Nephrology : JASN.

Ferric citrate controls phosphorus and delivers iron in patients on dialysis.

J. Lewis, T. Greene, M. Koury, 2015, Journal of the American Society of Nephrology : JASN.

Ferric citrate: a novel phosphate-binding agent

J. Lewis, J. Dwyer, K. Umanath, 2013, Expert Review of Endocrinology & Metabolism.

292 A Dose-Ranging and Efficacy Phase 3 Trial of Ferric Citrate (FC) as a Phosphate Binder in Dialysis Patients

J. Lewis, M. Kaplan, G. Schulman, 2011 .

286: Iron Absorption With Higher Doses of Ferric Citrate in Controlling Serum Phosphorus in ESRD Patients

J. Lewis, T. Greene, S. Korbet, 2010 .

287: The Safety and Tolerability of Higher Doses of Ferric Citrate (FC) in Controlling Serum Phosphorus (P) In ESRD Patients

J. Lewis, T. Greene, S. Korbet, 2010 .

Effects of telmisartan, irbesartan, valsartan, candesartan, and losartan on cancers in 15 trials enrolling 138 769 individuals

Karl Swedberg, Richard B. Devereux, Ralph L. Sacco, 2011, Journal of hypertension.

Anti-Phospholipase A2 Receptor in Nonlupus Patients with Membranous Nephropathy and Crescents

J. Lewis, A. Fogo, J. Dwyer, 2021, Glomerular Diseases.

Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure: an individual participant-level data meta-analysis

R. Collins, B. Davis, M. Pfeffer, 2021, The Lancet.

Age-stratified and blood-pressure-stratified effects of blood-pressure-lowering pharmacotherapy for the prevention of cardiovascular disease and death: an individual participant-level data meta-analysis

R. Collins, B. Davis, M. Pfeffer, 2021, The Lancet.

Chapter 28 – Therapy for Diabetic Nephropathy

E. Lewis, J. Lewis, W. L. Whittier, 2008 .

A comparison of iothalamate-GFR and serum creatinine-based outcomes: acceleration in the rate of GFR decline in the African American Study of Kidney Disease and Hypertension.

L. Appel, J. Lewis, T. Greene, 2004, Journal of the American Society of Nephrology : JASN.

Evaluation of Variation in the Performance of GFR Slope as a Surrogate End Point for Kidney Failure in Clinical Trials that Differ by Severity of CKD

G. Remuzzi, C. Wanner, J. Lewis, 2023, Clinical journal of the American Society of Nephrology : CJASN.

Cardiovascular Outcomes in the Irbesartan Diabetic Nephropathy Trial of Patients with Type 2 Diabetes and Overt Nephropathy

M. Pfeffer, J. Rouleau, E. Lewis, 2003, Annals of Internal Medicine.

Long-term effects of renin-angiotensin system-blocking therapy and a low blood pressure goal on progression of hypertensive chronic kidney disease in African Americans.

Mahboob Rahman, Tom Greene, Lawrence J Appel, 2008, Archives of internal medicine.

Baseline characteristics of participants in the African American Study of Kidney Disease and Hypertension (AASK) Clinical Trial and Cohort Study.

L. Appel, T. Erlinger, J. Lewis, 2007, American journal of kidney diseases : the official journal of the National Kidney Foundation.

Rate of ESRD exceeds mortality among African Americans with hypertensive nephrosclerosis.

L. Appel, J. Lewis, T. Greene, 2010, Journal of the American Society of Nephrology : JASN.

Albuminuria Is an Appropriate Therapeutic Target in Patients with CKD: The Pro View

J. Lewis, L. Fried, 2015 .

Albuminuria is Not an Appropriate Therapeutic Target in Patients with CKD: The Con View.

J. Lewis, L. Fried, 2015, Clinical journal of the American Society of Nephrology : CJASN.

Blood pressure control in chronic kidney disease: is less really more?

J. Lewis, 2010, Journal of the American Society of Nephrology : JASN.

CRP polymorphisms and progression of chronic kidney disease in African Americans.

E. Siew, A. Hung, T. Ikizler, 2010, Clinical journal of the American Society of Nephrology : CJASN.

Nephrotic syndrome in diabetic kidney disease: an evaluation and update of the definition.

C. Schmid, R. Atkins, L. Stevens, 2009, American journal of kidney diseases : the official journal of the National Kidney Foundation.

Effects of Intensive Blood Pressure Treatment on Acute Kidney Injury Events in the Systolic Blood Pressure Intervention Trial (SPRINT).

Anna C. Porter, K. Sink, M. Rocco, 2018, American journal of kidney diseases : the official journal of the National Kidney Foundation.

Design and statistical aspects of the African American Study of Kidney Disease and Hypertension (AASK).

M. Kutner, G. Beck, G. Bakris, 2003, Journal of the American Society of Nephrology : JASN.

Baseline predictors of renal disease progression in the African American Study of Hypertension and Kidney Disease.

Keith C. Norris, L. Appel, J. Lewis, 2006, Journal of the American Society of Nephrology : JASN.

Guidelines and Straitjackets: blood pressure targets in the era of the Eighth Joint National Committee.

J. Lewis, A. Burgner, J. Dwyer, 2014, American journal of kidney diseases : the official journal of the National Kidney Foundation.

Optimizing blood pressure control in patients with nondiabetic glomerular disease.

J. Lewis, J. Dwyer, K. Umanath, 2014, Advances in chronic kidney disease.

Adherence rates to ferric citrate as compared to active control in patients with end stage kidney disease on dialysis

J. Lewis, T. Greene, D. Jalal, 2017, Hemodialysis international. International Symposium on Home Hemodialysis.

How Low Do We Go (in the Post-SPRINT Era)?

J. Lewis, A. Burgner, 2019, Advances in chronic kidney disease.

Social Determinants of Health and Their Impact on the Black Race Coefficient in Serum Creatinine–Based Estimation of GFR

A. Levey, J. Lewis, T. Greene, 2023, Clinical journal of the American Society of Nephrology : CJASN.

Specialist and primary care physicians’ views on barriers to adequate preparation of patients for renal replacement therapy: a qualitative study

Jessica M. Ameling, Raquel C. Greer, N. Powe, 2015, BMC Nephrology.

Atrial natriuretic factor in oliguric acute renal failure

J. Lewis, G. Chertow, M. Salem, 2000 .

Aliskiren in combination with losartan reduces albuminuria independent of baseline blood pressure in patients with type 2 diabetes and nephropathy.

E. Lewis, H. Parving, J. Lewis, 2011, Clinical journal of the American Society of Nephrology : CJASN.

Change in albuminuria as a surrogate endpoint for progression of kidney disease: a meta-analysis of treatment effects in randomised clinical trials.

J. Coresh, H. Tighiouart, A. Levey, 2019, The lancet. Diabetes & endocrinology.

Albuminuria and blood pressure, independent targets for cardioprotective therapy in patients with diabetes and nephropathy: a post hoc analysis of the combined RENAAL and IDNT trials.

T. Berl, H. Parving, G. Remuzzi, 2011, European heart journal.

Longitudinal progression trajectory of GFR among patients with CKD.

Liang Li, Tom H Greene, Bo Hu, 2012, American journal of kidney diseases : the official journal of the National Kidney Foundation.

Kidney function can improve in patients with hypertensive CKD.

B. Astor, L. Appel, J. Lewis, 2012, Journal of the American Society of Nephrology : JASN.

Effect of Sotagliflozin on Total Hospitalizations in Patients With Type 2 Diabetes and Worsening Heart Failure

Deepak L. Bhatt, P. Ponikowski, Lawrence A Leiter, 2021, Annals of Internal Medicine.

Predictors of cardiovascular events in patients with type 2 diabetic nephropathy and hypertension: a case for albuminuria.

M. Pfeffer, J. Rouleau, E. Lewis, 2004, Kidney international. Supplement.

A prospective cohort study of acute kidney injury and kidney outcomes, cardiovascular events, and death

J. Kaufman, A. Garg, A. Go, 2020, Kidney International.

Use of calcium antagonists in renal patients: Therapeutic benefit or medical malpractice?

J. Lewis, D. Nigbor, 2003, Current hypertension reports.

Black Americans' Perspectives of Barriers and Facilitators of Community Screening for Kidney Disease.

K. Abdel-Kader, J. Lewis, C. Wilkins, 2018, Clinical journal of the American Society of Nephrology : CJASN.

The safety of achieved iron stores and their effect on IV iron and ESA use: post-hoc results from a randomized trial of ferric citrate as a phosphate binder in dialysis .

J. Lewis, T. Greene, M. Koury, 2017, Clinical nephrology.

Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial.

Keith C. Norris, G. Beck, Mahboob Rahman, 2001, JAMA.

Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes.

E. Lewis, T. Berl, R. Atkins, 2001, The New England journal of medicine.

Prevalence and risk factors for microalbuminuria in a referred cohort of type II diabetic patients: a global perspective.

H. Parving, G. Remuzzi, J. Lewis, 2006, Kidney international.

Jugular bulb saturation and cognitive dysfunction after cardiopulmonary bypass.

W. White, L. Smith, J. Lewis, 1994, The Annals of thoracic surgery.

Effect of intensive blood pressure control on the course of type 1 diabetic nephropathy. Collaborative Study Group.

R. Bain, E. Lewis, T. Berl, 1999, American journal of kidney diseases : the official journal of the National Kidney Foundation.

Comparison of cross-sectional renal function measurements in African Americans with hypertensive nephrosclerosis and of primary formulas to estimate glomerular filtration rate.

J. Lewis, T. Greene, J. Wright, 2001, American journal of kidney diseases : the official journal of the National Kidney Foundation.

Remission of nephrotic syndrome in type 1 diabetes: long-term follow-up of patients in the Captopril Study.

R. Bain, E. Lewis, A. Levey, 1999, American journal of kidney diseases : the official journal of the National Kidney Foundation.

A meta-analysis of GFR slope as a surrogate endpoint for kidney failure

M. Landray, J. Chan, K. Mahaffey, 2023, Nature Medicine.

Residual proteinuria and eGFR predict progression of renal impairment within 2 years in type 2 diabetic patients with nephropathy who are receiving optimal treatment with angiotensin receptor blockers

R. Atkins, J. Lewis, A. Reutens, 2013, Nephrology.

Sulodexide fails to demonstrate renoprotection in overt type 2 diabetic nephropathy.

E. Lewis, T. Berl, J. Chan, 2012, Journal of the American Society of Nephrology : JASN.

Accuracy of a GFR estimating equation over time in people with a wide range of kidney function.

G. Beck, C. Schmid, H. Tighiouart, 2012, American journal of kidney diseases : the official journal of the National Kidney Foundation.

Focus on health information technology, electronic health records and their financial impact: A framework for evaluating the appropriateness of clinical decision support alerts and responses

Julie A. Wright, A. McCoy, J. Peterson, 2012, J. Am. Medical Informatics Assoc..

Renal pathology patterns in type II diabetes mellitus: relationship with retinopathy. The Collaborative Study Group.

E. Lewis, T. Leonard-Martin, J. Lewis, 1998, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

Racial differences in chronic kidney disease (CKD) and end-stage renal disease (ESRD) in the United States: a social and economic dilemma.

J. Lewis, J. Lewis, T. Palmer Alves, 2011, Clinical nephrology.

Design and statistical aspects of the African American Study of Kidney Disease and Hypertension (AASK).

M. Kutner, G. Beck, G. Bakris, 2003, Journal of the American Society of Nephrology : JASN.

Long-term effects of renin-angiotensin system-blocking therapy and a low blood pressure goal on progression of hypertensive chronic kidney disease in African Americans.

Keith C. Norris, Mahboob Rahman, L. Appel, 2008, Archives of internal medicine.

Proteinuria in Type 2 Diabetic Patients with Renal Impairment: The Changing Face of Diabetic Nephropathy

R. Atkins, J. Lewis, A. Reutens, 2010, Nephron Clinical Practice.

Sulodexide for kidney protection in type 2 diabetes patients with microalbuminuria: a randomized controlled trial.

E. Lewis, T. Berl, R. Atkins, 2011, American journal of kidney diseases : the official journal of the National Kidney Foundation.

Focus on health information technology, electronic health records and their financial impact: A framework for evaluating the appropriateness of clinical decision support alerts and responses

Julie A. Wright, A. McCoy, J. Peterson, 2012, J. Am. Medical Informatics Assoc..

Longitudinal progression trajectory of GFR among patients with CKD.

B. Astor, L. Appel, J. Lewis, 2012, American journal of kidney diseases : the official journal of the National Kidney Foundation.

Microalbuminuria: accuracy or economics.

J. Lewis, J. Lewis, 1998, American journal of kidney diseases : the official journal of the National Kidney Foundation.